Novo Nordisk believes sickle cell anemia market will double in value by decade end
The sickle cell anemia market is valued at around USD 5bn today – but according to Novo Head of Rare Disease Ludovic Helfgott, it will be worth as much as USD 10bn before 2030.
by mikkel holmgaard winding, translated by daniel pedersen
A premium of 92% is perfectly in line with what similar companies are being bought and sold for on today’s market, and is actually a fair price, says Novo Nordisk Head of Rare Disease Ludovic Helfgott.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to acquire Forma Therapeutics in USD 1.1bn deal
For subscribers
Novo Nordisk enters USD 6.3m legal settlement in US
For subscribers
